Oscar Health, Inc. (NYSE:OSCR) Director Thrive Partners Vii Growth Gp, Buys 420,819 Shares of Stock

Oscar Health, Inc. (NYSE:OSCR) Director Thrive Partners Vii Growth Gp, purchased 420,819 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $13.68 per share, for a total transaction of $5,756,803.92. Following the purchase, the director now owns 5,452,081 shares of the company’s stock, valued at approximately $74,584,468.08. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Oscar Health Price Performance

Shares of NYSE:OSCR opened at $13.48 on Thursday. The company has a market cap of $3.26 billion, a PE ratio of -224.63, a P/E/G ratio of 12.49 and a beta of 1.67. Oscar Health, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $23.79. The firm has a 50-day simple moving average of $18.28 and a 200 day simple moving average of $18.30. The company has a quick ratio of 0.91, a current ratio of 0.73 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The company had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The company’s revenue for the quarter was up 68.3% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS. On average, sell-side analysts anticipate that Oscar Health, Inc. will post -0.01 EPS for the current year.

Hedge Funds Weigh In On Oscar Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Oscar Health by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 14,582,762 shares of the company’s stock valued at $216,846,000 after purchasing an additional 337,850 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Oscar Health by 153.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock worth $59,156,000 after buying an additional 2,409,160 shares in the last quarter. Renaissance Technologies LLC increased its position in Oscar Health by 31.7% in the 2nd quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company’s stock valued at $61,478,000 after acquiring an additional 934,600 shares during the period. First Light Asset Management LLC raised its stake in Oscar Health by 117.3% during the 1st quarter. First Light Asset Management LLC now owns 2,102,554 shares of the company’s stock valued at $31,265,000 after acquiring an additional 1,134,919 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Oscar Health by 32.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company’s stock worth $32,368,000 after acquiring an additional 507,009 shares during the period. Institutional investors and hedge funds own 75.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on OSCR shares. Bank of America lowered Oscar Health from a “neutral” rating to an “underperform” rating and cut their target price for the company from $21.00 to $13.50 in a research report on Wednesday, November 6th. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Oscar Health in a report on Tuesday, September 10th. Finally, UBS Group began coverage on shares of Oscar Health in a research note on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.93.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.